CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
从免疫调节剂（IMiDs）到 cereblon E3 连接酶调节剂（CELMoDs）：cereblon 调节剂在淋巴瘤治疗中的演变
英文原题：From immunomodulators (IMiDs) to cereblon E3 ligase modulator (CELMoDs): the evolution of cereblon modulators in lymphoma therapy.
查看英文原题
From immunomodulators (IMiDs) to cereblon E3 ligase modulator (CELMoDs): the evolution of cereblon modulators in lymphoma therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
脑磷脂 E3 连接酶调节药物（CELMoD）是新一代免疫调节剂（IMiD），具有有希望的疗效和安全性特征。早期临床试验显示，该类药物对既往 IMiD 或 CAR-T 等细胞免疫疗法治疗失败、接受多线治疗的淋巴瘤患者具有临床活性。CELMoD 有望成为一种固定疗程、无化疗方案，在复发/难治性（R/R）及初治 B 细胞非霍奇金淋巴瘤（B-NHL）中带来持久应答。本综述探讨脑磷脂（CRBN）在淋巴瘤发生中的关键作用，并介绍 IMiD 和 CELMoD 靶向 CRBN 的机制。此外，文章讨论评估这些新型药物单药及联合方案在一线和 R/R 治疗中的早期临床试验主要发现。最后，综述关注正在开展的临床试验，并探讨 CELMoD 如何改变当前治疗格局、潜在重新定义 B 细胞淋巴瘤标准治疗。
展开英文摘要原文
Cereblon E3 ligase modulating drugs (CELMoDs) are next-generation immunomodulators (IMiDs) with a promising efficacy and safety profile. Early-phase clinical trials have shown clinical activity in heavily pretreated lymphomas, including those refractory to prior IMiD therapy or to cellular immunotherapies such as CAR-T.
CELMoDs show potential as a fixed-duration, chemo-free option with durable responses in both relapsed/refractory (R/R) and treatment-na ve B-NHL. This review offers an exploration of cereblon (CRBN) as key for lymphomagenesis and highlights the mechanisms by which IMiDs and CELMoD target CRBN.
Additionally, we discussed the key findings from early-phase clinical trials evaluating these newer agents as monotherapy and in combination regimens across first-line and R/R settings.
Finally, we focused on ongoing clinical trials and discussed how CELMoDs may reshape the current treatment landscape and potentially redefine the standard of care in B-cell lymphomas.
论文信息
- 作者
- Saha A、Jhaveri K、Perini GF、Chavez JC
- 第一作者单位
- Department of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.United Kingdom
- 通讯作者单位
- Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, USA.United States
- 文献类型
- 综述
- 期刊
- Leukemia & lymphoma2026 Jun
- 原文标识
- PubMed 42154229 · DOI 10.1080/10428194.2026.2662494